{"drugs":["Fosrenol","Lanthanum Carbonate"],"mono":{"0":{"id":"928332-s-0","title":"Generic Names","mono":"Lanthanum Carbonate"},"1":{"id":"928332-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928332-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>End stage renal disease - Hyperphosphatemia:<\/b> initial, 1500 mg ORALLY per day in divided doses with meals, then titrate in increments of 750 mg\/day at intervals of 2 to 3 weeks<\/li><li><b>End stage renal disease - Hyperphosphatemia:<\/b> maintenance, 1500 to 3000 mg ORALLY per day in divided doses with meals<\/li><\/ul>"},"1":{"id":"928332-s-1-5","title":"Pediatric Dosing","mono":"use in pediatric patients is not recommended "},"3":{"id":"928332-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>End stage renal disease - Hyperphosphatemia<br\/>"}}},"3":{"id":"928332-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928332-s-3-9","title":"Contraindications","mono":"bowel obstruction, ileus, or fecal impaction <br\/>"},{"id":"928332-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- gastrointestinal obstruction, ileus, and fecal impaction, including serious cases requiring surgery or hospitalization, have been reported<\/li><li>-- altered gastrointestinal anatomy (eg, prior gastrointestinal surgery, colon cancer); increased risk for bowel obstruction, ileus, or fecal impaction<\/li><li>-- hypomotility disorders (eg, constipation, ileus, diabetes); increased risk for bowel obstruction, ileus, or fecal impaction<\/li><li>Other:<\/li><li>-- abdominal X-rays may have a radio-opaque appearance similar to an imaging agent<\/li><\/ul>"},{"id":"928332-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"928332-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"4":{"id":"928332-s-4","title":"Drug Interactions","sub":{"2":{"id":"928332-s-4-15","title":"Moderate","mono":"<ul><li>Balofloxacin (probable)<\/li><li>Besifloxacin (probable)<\/li><li>Ciprofloxacin (probable)<\/li><li>Enoxacin (probable)<\/li><li>Flumequine (probable)<\/li><li>Gatifloxacin (probable)<\/li><li>Gemifloxacin (probable)<\/li><li>Levofloxacin (probable)<\/li><li>Levothyroxine (probable)<\/li><li>Lomefloxacin (probable)<\/li><li>Moxifloxacin (probable)<\/li><li>Nadifloxacin (probable)<\/li><li>Norfloxacin (probable)<\/li><li>Ofloxacin (probable)<\/li><li>Pazufloxacin (probable)<\/li><li>Pefloxacin (probable)<\/li><li>Prulifloxacin (probable)<\/li><li>Rufloxacin (probable)<\/li><li>Sparfloxacin (probable)<\/li><\/ul>"}}},"5":{"id":"928332-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Abdominal pain (5%), Diarrhea, Nausea (11%.), Vomiting (9%.)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Vascular graft occlusion, Dialysis<\/li><li><b>Gastrointestinal:<\/b>Bowel obstruction, Fecal impaction, Gastrointestinal obstruction<\/li><\/ul>"},"6":{"id":"928332-s-6","title":"Drug Name Info","sub":{"0":{"id":"928332-s-6-17","title":"US Trade Names","mono":"Fosrenol<br\/>"},"2":{"id":"928332-s-6-19","title":"Class","mono":"Phosphate Binder<br\/>"},"3":{"id":"928332-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928332-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928332-s-7","title":"Mechanism Of Action","mono":"Lanthanum carbonate reduces serum phosphate in patients with ESRD. It inhibits the absorption of dietary phosphate by forming highly insoluble lanthanum phosphate complexes.<br\/>"},"8":{"id":"928332-s-8","title":"Pharmacokinetics","sub":[{"id":"928332-s-8-23","title":"Absorption","mono":"<ul><li>Bioavailability, Oral: less than 0.002%<\/li><li>Effect of food:. Negligible when given during or 30 minutes after a meal; not recommended to be used with enteral nutrition<\/li><\/ul>"},{"id":"928332-s-8-24","title":"Distribution","mono":"Protein binding: greater than 99% <br\/>"},{"id":"928332-s-8-25","title":"Metabolism","mono":"Not metabolized; not a substrate of CYP450 <br\/>"},{"id":"928332-s-8-26","title":"Excretion","mono":"Renal: less than 2% <br\/>"},{"id":"928332-s-8-27","title":"Elimination Half Life","mono":"53 hours <br\/>"}]},"9":{"id":"928332-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>Chewable tablets: Chew completely or crush tablets to aid chewing before swallowing; do not swallow intact tablets<\/li><li>Oral powder: Sprinkle on applesauce or other soft food and administer immediately; do not premix future doses or open packet in advance; do not attempt to mix with liquids as powder is insoluble<\/li><li>for patients with poor dentition, consider use of oral powder<\/li><li>take with or immediately after meals<\/li><\/ul>"},"10":{"id":"928332-s-10","title":"Monitoring","mono":"serum phosphate level; as needed during titration, regularly after target concentration achieved (ie, less than 6 mg\/dL)<br\/>"},"11":{"id":"928332-s-11","title":"How Supplied","mono":"<b>Fosrenol<\/b><br\/><ul><li>Oral Powder: 750 MG, 1000 MG<\/li><li>Oral Tablet, Chewable: 500 MG, 750 MG, 1000 MG<\/li><\/ul>"},"13":{"id":"928332-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report symptoms of gastrointestinal obstruction, ileus, or fecal impaction.<\/li><li>Side effects may include abdominal pain, diarrhea, nausea, or vomiting.<\/li><li>Tell patient to alert physician prior to an abdominal x-ray that drug is being used, as drug is radio-opaque.<\/li><li>Advise patient to take with or immediately after food.<\/li><li>Instruct patient to thoroughly chew or crush tablet prior to swallowing.<\/li><li>Direct patient to sprinkle oral powder on a small amount of applesauce or similar food and consume immediately. Do not mix with liquids.<\/li><\/ul>"}}}